mrpubmed

Sorry, don't know exactly what this is, but seems to be a type of
homonal manipulation. Mighty low numbers for a study though.

Urology. 2004 Jan;63(1):13-6.
Related Articles, Links


Role of mepartricin in category III chronic nonbacterial
prostatitis/chronic pelvic pain syndrome: a randomized prospective
placebo-controlled trial.

De Rose AF, Gallo F, Giglio M, Carmignani G.

Luciano Giuliani Urology Department, University of Genoa, Genoa,
Italy.

OBJECTIVES: To verify the efficacy of mepartricin versus placebo with
regard to symptom improvement in patients with chronic nonbacterial
prostatitis/chronic pelvic pain syndrome (CPPS) and to verify a
relation between hormonal levels and clinical improvement in these
patients. METHODS: Twenty-six patients with CPPS were included in our
study and randomized into two groups of 13 subjects each. Group 1
patients were treated with mepartricin (40 mg daily) and group 2
patients with placebo. All patients underwent treatment for 60 days.
At the beginning and end of therapy, all patients underwent
evaluation, including a standardized history, physical examination,
luteinizing hormone, follicle-stimulating hormone, testosterone, and
beta-estradiol measurements, and a National Institutes of
Health-Chronic Prostatitis Symptom Index (NIH-CPSI) questionnaire.
RESULTS: We observed a decrease in the total NIH-CPSI score from 25.0
to 10.0 in group 1 and from 25.0 to 20.0 in group 2, revealing a 60%
and 20% improvement in groups 1 and 2, respectively. A statistically
significant decrease was observed with regard to pain (from 11.0 to
4.0 and from 10.0 to 8.0, respectively) and quality of life (from 10.0
to 5.0 and 10.0 to 9.0, respectively). No statistically significant
difference was observed in urinary dysfunctions. The luteinizing
hormone, follicle-stimulating hormone, and testosterone values were
similar in both groups before and after treatment; the
17-beta-estradiol levels were significantly lower in group 1 compared
with group 2 at the end of the study. CONCLUSIONS: Mepartricin
provides significant symptomatic improvement in men with CPPS compared
with placebo. The role of mepartricin in decreasing estrogen plasmatic
levels and their concentration in the prostate may account for this
clinical improvement.